Historical development of saralasin.

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Research

Background:

• Angiotensin II (AII) plays a key role in blood pressure regulation.
• Development of AII antagonists is crucial for managing hypertension.
• Aminopeptidase degradation limits the efficacy of peptide-based drugs.

Observation:

• Sarcosine substitution in [Sar1, Val5, Ala8]-AII (saralasin) was initially intended to prevent aminopeptidase breakdown.
• Saralasin demonstrated unexpected increases in affinity for vascular smooth muscle receptors.
• Laboratory studies indicated saralasin's potential as a therapeutic and diagnostic agent.

Findings:

• Saralasin effectively antagonizes angiotensin II.
• The sarcosine modification confers resistance to aminopeptidase degradation.
• Saralasin exhibits significantly increased binding affinity to AII receptors.
• Clinical trials confirmed saralasin's utility in hypertensive patients.

Implications:

• Saralasin serves as a valuable tool for studying the renin-angiotensin system.
• Its unique properties offer potential for novel antihypertensive therapies.
• The development of saralasin highlights the benefits of rational drug design and serendipitous discovery.